Lucid gains NIH grant for in-vivo confocal microscopy technology
Lucid Inc. has received a $1.9 million, 3-year grant from the National Institute of Health's (NIH) National Cancer Institute (NCI) to perform a large clinical study to evaluate the efficacy of its VivaScope in-vivo confocal microscopy technology for the diagnosis of pigmented lesions in preventing melanoma. Lucid's VivaScope confocal microscopy can non-invasively image skin in-vivo with cellular resolution. This potentially permits pathologic diagnosis without the need to excise tissue, and may one day eliminate the need for routine invasive skin biopsy.
"The need for early detection is crucial to a melanoma patient's long-term survival of this disease," said Jay Eastman, chairman and CEO of Lucid, Inc. "This grant represents one of the steps required to bring a revolutionary medical device to the market that combines early detection capabilities with a painless, non-surgical procedure."
New PET imaging technology has allowed doctors to identify a person's specific kidney tumor type prior to surgery, based on research conducted at Memorial Sloan-Kettering Cancer Center in New York. Theses advances will enhance research for PET technology and encourage mass acceptance and widespread use.
"The need for early detection is crucial to a melanoma patient's long-term survival of this disease," said Jay Eastman, chairman and CEO of Lucid, Inc. "This grant represents one of the steps required to bring a revolutionary medical device to the market that combines early detection capabilities with a painless, non-surgical procedure."
New PET imaging technology has allowed doctors to identify a person's specific kidney tumor type prior to surgery, based on research conducted at Memorial Sloan-Kettering Cancer Center in New York. Theses advances will enhance research for PET technology and encourage mass acceptance and widespread use.